The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.
Teclistamab will be administered subcutaneously (SC).
Other Name: JNJ-64007957
Inclusion Criteria: - Patient diagnosed with Relapsed or Refractory Multiple Myeloma - Patient exhausted all commercially approved and clinically appropriate (not patient or physician preference) treatment options, and is ineligible for a clinical trial
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC